Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations

Treatment strategies targeting programed cell death 1 (PD-1) or its ligand, PD-L1, have been developed as immunotherapy against tumor progression for various cancer types including non-small cell lung cancer (NSCLC). The recent pivotal clinical trials of immune-checkpoint inhibiters (ICIs) combined...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Ichidai, Morise, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745513/
https://www.ncbi.nlm.nih.gov/pubmed/35008669
http://dx.doi.org/10.3390/ijms23010245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745513/
https://www.ncbi.nlm.nih.gov/pubmed/35008669
http://dx.doi.org/10.3390/ijms23010245

Ejemplares similares